Author

E.-J. Kwon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

H.-J. Cha· 2 shared A. Adpaikar· 1 shared B. K. Koo· 1 shared B. W. Han· 1 shared B.-K. Jo· 1 shared C. P. Hong· 1 shared E.-J. Kim· 1 shared H. Lee· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

H.-J. Cha

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Partial in vivo reprogramming enables injury-free intestinal regeneration via autonomous Ptgs1 induction

J. Kim, S. Kim, S.-Y. Lee, B.-K. Jo, J.-Y. Oh, E.-J. Kwon, K.-T. Kim, A. Adpaikar, E.-J. Kim, H.-S. Jung, H.-R. Kim, J.-S. Roe, C. P. Hong, J. K. Kim, B. K. Koo, H.-J. Cha

This study shows that partial in vivo reprogramming using OSKM factors induces intestinal regeneration via Ptgs1-driven prostaglandin synthesis, distinct from normal Ptgs2-dependent regeneration.

bioRxiv · Feb 25, 2023 · PreprintCell Biology

Identification of a novel HASPIN inhibitor and its synergism with the PLK1 inhibitor

E.-J. Kwon, K. Mashelkar, J. Seo, Y. Shin, K. Sung, S. C. Jang, S. W. Cheon, H. Lee, B. W. Han, L. S. Jeong, H.-J. Cha

The paper identifies a novel HASPIN inhibitor, LJ4827, and shows its synergistic effect with PLK1 inhibitor BI2536 in lung cancer treatment.

bioRxiv · Sep 1, 2022 · PreprintPharmacology & Toxicology